Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Permitted use of Pharma in Focus

Pharma in Focus includes both free and protected content. Free content is available to all users. Protected content is only available to registered users.

Permitted Use of Pharma in Focus protected content

  1. Pharma in Focus protected content is for the personal use of registered users only. Registered users are those who have paid a subscription for access to protected content. Protected content is any content not made available free of charge on the Pharma in Focus site or via the Pharma in Focus News Alert email.

  2. Registered users may:

    a) Access Pharma in Focus material either from their workplace computer or at home or at a remote computer if away temporarily.

    b) Make one hard copy for personal use

    c) Use the 'email a friend' facility in keeping with condition 3(a) below

  1. Registered users may not:

    a) use the 'email a friend' facility to redistribute Pharma in Focus as a whole or in any quantity or frequency which amounts to any person having substantially the benefit of unrestricted access to Pharma in Focus without having paid a subscription or having a subscription paid on their behalf

    b) use their registered email address, or permit it to be used, to allow others gain access to Pharma in Focus

    c) redistribute Pharma in Focus material to anyone by any other means.

TOP | BACK

Approvals Action
Gilead's Viread replacement registered
Gilead has won registration for chronic hepatitis B treatment Vemlidy, its replacement drug for Viread in that indication, which will soon be facing generic competition.
Pipeline Monitor
Celgene scores with old and new drugs
Celgene's Revlimid has won an additional indication in the US while the company's potential blockbuster, ozanimod, has enjoyed success in a head-to- had trial against Biogen's Avonex.
Debating Point
Expert games not very convincing
Both sides in the battle over the future of biosimilar prescribing in Australia have been rolling out their foreign experts but it's hard to see how fly-in, fly-out expertise can influence a government facing multiple budget management problems at home.